Exact Sciences' Preliminary Q4 2024 Results: Strong Growth in Screening, Modest Precision Oncology Performance
Marcus LeeSunday, Jan 12, 2025 7:09 pm ET
1min readExact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, has announced its preliminary fourth quarter 2024 results, showcasing robust performance in its Screening segment and a modest increase in Precision Oncology revenue. The company expects total revenue of $713 million for the quarter, up 10% year-over-year, driven by a 14% increase in Screening revenue and a 0.4% increase in Precision Oncology revenue.
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
Comments
No comments yet